VANCOUVER, Oct. 25 /PRNewswire-FirstCall/ - Biotech Holdings reports that it has signed an agreement, with a private company based in El Salvador for marketing and distribution of its Sucanon Type II diabetes drug in four Central American countries, Guatemala, Honduras, Nicaragua and El Salvador.
The four new markets targeted in connection with this agreement have a total population of approximately 33 million people, with an estimated 775,000 cases of Type II Diabetes in the region.
The Central American markets will be served by Sucanon deliveries from the Company's contract-packager, based in Mexico City. The distributor will co-ordinate its advertising in the Central American region with advertising arranged by Biotech's office in Mexico.
This release has been approved by the Board of Directors of Biotech Holdings.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed. There is no assurance that regulatory approval will be obtained in any specific market nor any assurance that sales, once begun, will be material.
CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or firstname.lastname@example.org; For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com
CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or
email@example.com; For background information on Biotech Holdings, or to
receive news updates, see www.biotechltd.com